anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Critically ill patients admitted to the intensive care unit often have anemia from one or more of a number of possible causes including blood loss due to surgery or injury, frequent blood sampling, chronic diseases such as kidney failure or cancer or treatments being received, such as chemotherapy. Although the common treatment for anemia is red blood cell transfusion, the current guidelines for blood transfusions for children are based on available information regarding transfusions in adults. Since many characteristics specific to critically ill children may affect the way in which they respond to anemia and transfusion, additional information is needed to better define guidelines for the prevention and treatment of anemia in critically ill children. This is a multi-center study to collect information regarding the management of anemia in critically ill children. Information needed to evaluate anemia, blood loss and transfusions will be collected from the patients' hospital records. No blood draws or procedures will be required by this survey and no medication will be supplied by the study Sponsor. Each patient's treating physician will be responsible for all decisions regarding his/her clinical care and treatment during the study. Approximately 1200 patients will be enrolled into this study, which is divided into 2 parts. During part 1, at least 400 patients who are newly admitted to the Pediatric Intensive Care Unit (PICU) will be enrolled, regardless of their length of stay in the PICU. During part 2, up to an additional 800 patients who are newly admitted into the PICU and have remained there for \> = 48 hours at the time of entry into the study will be enrolled. Information for each patient will be collected for up to 28 days or until time of discharge from the hospital or death of the patient, whichever occurs first. Blood loss will be reported for each day the patient remains in the PICU; information regarding the treatment of anemia, including number and reasons for transfusions will be collected for a maximum of 28 days, regardless of the length of stay in the PICU. Information collected at the time of discharge from the hospital will include date of discharge and whether or not the patient is receiving mechanical assistance to breathe. Several possible hypotheses are being generated in this study: 1) Blood loss due to procedures and routine laboratory tests may be a major cause of anemia and transfusions in critically ill children; 2) Determining significant causes of anemia and blood transfusions in children will allow for better future treatment of anemia; and 3) Pediatric patients who receive blood transfusions have more days on a ventilator (a machine that helps patients who cannot breathe on their own), longer stays in the PICU and decreased organ function. Since the study involves only collection of information, no treatment will be required by the Sponsor and no medication will be supplied by the Sponsor.
Today, approximately 5 million Americans of reproductive age have Polycystic Ovary Syndrome (PCOS). The personal and public health burden of PCOS is high. People with PCOS are at elevated risk of infertility, endometrial cancer, obesity, diabetes, dyslipidemia and nonalcoholic fatty liver disease (NAFLD). Moreover, there is a paucity of treatments that address the metabolic and reproductive concerns of this disorder. Obstructive sleep apnea (OSA) is a recognized co-morbidity of PCOS that may exacerbate both metabolic and reproductive aspects of PCOS. Thus, treating OSA represents a potentially attractive tool to improve outcomes in PCOS. Indeed, continuous positive airway pressure therapy (CPAP) is a relatively inexpensive treatment for OSA that is safe for use in women in the reproductive years, even when pregnant or trying to conceive. However, evidence regarding the impact of CPAP use in PCOS populations is lacking, and, currently, screening and treatment of OSA is only considered standard of care to treat symptoms of excessive sleepiness or hypertension. Because an estimated 15-45% of people with moderate/severe OSA do not have these symptoms, treatment is not considered standard of care for the majority of persons with OSA and PCOS. From another study looking at sleep and PCOS, we will identify 20 subjects with moderate-to-severe OSA without excessive daytime sleepiness who will enroll in a CPAP trial. These subjects will undergo intensive multi-tissue insulin resistance testing and will be assigned treatment with CPAP or delayed treatment after 12 weeks after which all measures will be re-assessed. Accordingly, this proposal will address an unanswered question: Does CPAP provide metabolic or reproductive benefits in PCOS? The results will also better define potential mechanistic pathways linking OSA to insulin resistance and will determine whether CPAP improves key outcomes.
BACKGROUND: Incidence of infective endocarditis (IE) is progressively raising because of the increasing number of cardiovascular invasive procedures, support treatment and devices, awareness in the medical community, and improved diagnostic modalities. IE pathophysiology is a unique model of immunothrombosis, and the clinical course is often complicated by either embolic or hemorrhagic events. Managing antithrombotic treatment is challenging and the level of supporting evidence scant. The aim of this review was to discuss and present the embolic and bleeding complication associated with IE and review the available evidence on antithrombotic treatment in patients with IE with and without a previous indication to antithrombotic drugs.
SUMMARY: Embolic events occur in 20-40% of patients with IE and are associated with high morbidity and mortality. Acute ischemic stroke is the most common neurological complication. A beneficial effect of antithrombotic therapy in preventing ischemic stroke for patients with IE has never been formally tested in adequately powered randomized clinical trials. Atrial fibrillation is a common complication associated with severe infections, requiring anticoagulation. Furthermore, patients with IE have a high risk of unprovoked and anticoagulation treatment-related bleeding. In particular, intracerebral bleeding is the most severe complication in about 5% of patients with IE. Single antiplatelet therapy with low-dose aspirin after hospitalization for IE has been shown to reduce causes mortality within 90 days without an increase of hemorrhagic strokes. In the absence of bleeding complications, recent guidelines recommend to maintain low-dose aspirin. No data are available on the management of patients with IE while on dual antiplatelet therapy.
KEY MESSAGES: Several gaps in knowledge remain about antithrombotic management in patients with IE and most of the evidence relies on observational studies. Individualized strategies based on clinical evaluation, comorbidities, patient engagement, and shared decisions strategies are encouraged.
A system for recording health data includes a measurement device that obtains measurements of a health characteristic and a processing device communicatively connected to the measurement device. The processing device receives the measurement results from the measurement device and includes a processor, a user interface, and at least one memory device. The at least one memory device stores measurement results and computer-readable instructions for a healthcare application. The processor executes a healthcare application. The healthcare application displays and receives supplemental health data associated with the measurement via the user interface. At least one memory device stores a future date. The healthcare application prompts the user to take measurements according to the first plan for a first period of time prior to a future date. In response to the at least one memory device receiving the future date, the healthcare application prompts the user to obtain measurements according to the second plan for a second time period prior to the future date.
BACKGROUND: Due to cultural, economic, and societal factors, immigrants and refugees are pivotal groups in dealing with social vulnerability in disasters. Ignoring or inadequate attention to those groups in preparing for and responding to disasters and health emergencies could decrease the effectiveness of efforts. This article aims to identify the most basic social vulnerabilities among immigrants and refugees and provide effective solutions to alleviate or eliminate these vulnerabilities.
METHODS: This systematic review was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The main keywords include Social Vulnerabilities, Immigrants, Refugees, and Disasters. All articles published up to February 2023 were reviewed regardless of language and location. A total of 575 articles were extracted from SCOPUS, Web of Science, ScienceDirect, ProQuest, PubMed, EMBASE, and PsycINFO databases, and finally, 14 articles were selected for full-text analysis. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) was used to evaluate the quality of the selected articles.
RESULTS: Fourteen articles including 4 qualitative and 10 quantitative articles were selected and analyzed in this review. The findings showed: 1. According to the consensus of the studies, the most vulnerable people who need urgent care during an epidemic due to their special conditions are immigrants and refugees; 2. In most countries, no database provides reliable, up-to-date, and accurate statistics about these people; 3. Refugees usually hesitate to express their vulnerability and receive services due to the fear of deportation; and 4. The main challenges faced by refugees are socio-economic problems such as language problems, lack of emotional and social support, and living in crowded places.
CONCLUSION: Considering the prevalence of migration among countries, it is essential to identify the social problems and vulnerabilities of immigrants and provide effective solutions to cope with their challenges, especially during crises and emergencies.
SYSTEMATIC REVIEW REGISTRATION: https://clinicaltrials.gov/, identifier CRD42022371345.
Acute kidney injury (AKI) is defined as a rapid decline in renal function, in which persistent kidney dysfunction gradually progresses to chronic kidney disease (CKD) due to the irreversible loss of nephrons and their maladaptive repair. In recent years, the incidence of AKI has been increasing concerning diverse etiologies, including volume depletion, sepsis, nephrotoxicity, muscle injury, and major trauma, in which ischemia-reperfusion injury (IRI) accounts for most episodes. Development of the IRI model in mice is induced by surgical clamping of the renal pedicles, which provides powerful and controllable tools for preclinical models of AKI. Importantly, the IRI model is deployed at different stages of the AKI development, especially in the processes of AKI to CKD. Despite the IRI model being widely practiced in many laboratories, a series of variables still influence the results of this model. Here, we describe the procedure of IRI model development to provide a repeatable and reliable method for researchers to explore the underlying pathogenesis in the development of AKI and the progression of AKI to CKD.
Prior research has shown that racial discrimination (RD) impacts activation in threat network regions, including the ventromedial prefrontal cortex (vmPFC) and middle occipital cortex during attention to threat-relevant stimuli. However, little is known about the biological mechanisms that may modulate these effects; inflammation may be a pathway linking RD and threat network activation. As such, the current study aimed to explore whether systemic inflammation, measured by C-reactive protein (CRP) levels, may moderate the relationship between RD and activation in the vmPFC and middle occipital cortex during attention to threat. Blood samples for inflammatory marker (CRP) assays were obtained from forty Black American women (mean [SD] age, 39.93 [9.97] years; range, 22-58 years) recruited from an ongoing trauma study; participants also viewed threat-relevant stimuli as part of an attention task during fMRI. We found that CRP moderated the relationship between RD and vmPFC activation during attention to threat, such that participants with relatively higher concentrations of CRP ( ≥ 23.97 mg/L) demonstrated significant positive associations between RD and vmPFC activation [β = 0.18, CI (0.04, 0.32), t = 2.65, p = 0.01]. No significant associations were observed for participants who showed moderate (10.89 mg/L) or low (0.20 mg/L) CRP concentrations. CRP did not moderate the relationship between RD and middle occipital cortex activation. Our data present a mechanism through which RD may influence immune system activation and, in turn, threat network activation. Inflammation may contribute to brain health vulnerabilities in Black Americans via its effects on threat circuits; this merits further investigation in large-scale studies.
Osteoporosis (OP) is a bone disease characterized by reduced bone density and deterioration of bone tissue, leading to an increased risk of fractures. According to Calis et al; it was found that patients with hip fracture had a significantly higher Q angle compared to patients without hip fracture. According to You et al; contraction of the quadriceps muscles corrects the Q angle, therefore sports that use high amounts of quadriceps (strength) training are associated with lower Q angles due to the pulling effect of the quadriceps muscle. There are no studies evaluating Q angle in patients with OP and Osteopenia (OPN) in the literature. Therefore, the aim of this study was to examine the Q angle in patients diagnosed with OP and OPN and to compare it with patients diagnosed with OA. The study will be carried out by measuring the Q angle measurement with a goniometer. Pain assessment will be done with Visual Analog Scale (VAS). Lower extremity muscle strength will be assessed with the Medical Research Council (MRC) Scale. Foot posture will be assessed with the Foot Posture Index (FPI).
Disclosed is a preparation for oral administration which can reduce the residual amount of a medicinal composition and facilitate the swallowing of the medicinal composition. A preparation (10) for oral administration comprises an enclosing member (20) that is formed of an edible film. A medicinal composition (50) is enclosed in the enclosing member (20). The enclosing member (20) has a wall part (40). The wall part (40) is formed by rolling the edible film into a tubular shape. The wall part (40) has a part (60) where the edible film overlaps. The part (60) where the edible film overlaps is formed by rolling a single edible film sheet.
The present invention discloses a synthesis method of 5-hydroxy methyl-furazolidone. 1-chloroglycerine, hydrazine hydrate, sodium hydroxide, sodium methylate, dimethyl ester and 5-nitrofurfural diacetate are used as raw material for a reaction. The present invention is characterized in that the used hydrazine hydrate is water solution of hydrazine hydrate, wherein the concentration of the water solution of hydrazine hydrate is less than 100%. The present invention mainly solves the problems that hydrazine hydrate whose working concentration is 100% is required, and requirements for technical conditions are too high existing in a preparation method of 5-hydroxy methyl-furazolidone in the prior art. The present invention aims to provide a preparation method of 5-hydroxy methyl-furazolidone, which has the advantages that the preparation method is simple, the industrialization is easy, and the cost is almost equal to the cost of furazolidone. The present invention also solves the problem that lots of sodium chloride precipitates need processing in the preparation process of 5-hydroxy methyl-furazolidone in the prior art.
Ionic calcium (IC) is a calcium in a free ionic state. Participants will be instructed to take 8mg of IC/60kg body weight dissolved into approximately 500ml of purified water. Participants will titrate their dose at the start of the study as follows: days 1-3: 1 dose per day 30 min prior to a meal; Days 4-6: twice per day, 30 minutes before meals; from day seven onward, the full dosage of three times per day, 30 minutes before meals.
Participants randomized to this group will be taught how to perform focused breathing for the self-management of anxiety and asked to practice for 4 minutes each day during a six week period. They may practice focused breathing in addition to the twice daily practices if they experience anxiety. They will be asked to document in a diary each time they practice focused breathing.
Oral administration of placebo (1 capsule containing two placebo tablets) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
A subset of men with TBI meeting study criteria with normal T at screening were assessed at all data collection time points to provide a control group. Thirty-eight men obtained normal T levels at screening of which 24 were followed.
In this randomized trial, consenting individuals seeking inpatient opioid detoxification will be assigned to one of two groups. The first group will receive a tapering schedule of buprenorphine during inpatient detoxification to alleviate acute withdrawal symptoms, and referral to a community medical and substance abuse treatment providers (DETOX). The second group will also receive buprenorphine to relieve withdrawal symptoms, but will maintain a stable dose of buprenorphine through inpatient discharge and linkage to an appointment with a primary care provider within a week of discharge (LINKAGE). All participants complete study assessments at baseline, 1-month, 3-months and 6-months post-enrollment.

The SSTAR inpatient detoxification program based in Fall River, Massachusetts will serve as the recruitment site of this trial. SSTAR's program has 38 beds and is a 24-hour medically and psychiatrically supervised treatment facility that provides evaluation and withdrawal management. The SSTAR Family Healthcare Center is a 330 Federally Qualified facility also in Fall River that provides primary care and behavioral health services to residents of Community Health Network Area 25 (Fall River, Somerset, Swansea and Westport, Massachusetts). Dr. Bailey, Director of Research at SSTAR, will oversee the provision of buprenorphine treatment to study participants during detoxification and serve as liaison to the primary care providers at the Family Healthcare Center.
CD28H (TMIGD2 or IGPR-1) belongs to the CD28 family and is a transmembrane protein with an immunoglobulin-like extracellular domain, a transmembrane domain and a cytoplasmic tail. The main objective of the inventors was to evaluate the consequences of CD28H stimulation on NK with a monoclonal anti-CD28H antibody (clone 4-5) known to activate T cells. The inventors show that circulating CD56bright and CD56dim NK cells express the same level of CD28H. Circulating CD28H+ NK cells are more activated than CD28Hneg, in fact NK CD28H+ cells express more CD69, NKp30 and Nkp46. The agonist anti-CD28H mAb induces a calcium flux in NK cells while the blocking mAb does not. Calcium flux evaluation shows that CD28H synergize with NKP46 but not with CD16. After an overnight stimulation with the agonist anti-CD28H mAb, NK cells express more CD69, Nkp30, NKG2D and less CD16 compared to a control condition with an isotype mAb. This reflects a very strong activation of NK cells. Moreover, the CD28H-primed NK cells treated with the agonistic anti-CD28H mAb secret more granzyme B and more IFN-g in presence of K562. CD28H-primed NK cells increase their cytotoxic capacities against tumor cell lines. When used in vivo in a xeno-GVHD model in NSG-SGM3 mice, the agonistic anti-CD28H mAb increases the frequency of NK cells suggesting a potential role of CD28H in NK homeostasis. Thus CD28H is a strong activator of NK cells and is the potential new therapeutic target for cancer immunotherapy
CD8 + /TCR −  bone marrow cells facilitate engraftment of hemapoietic stem cells (HSQ in allogeneic recipients without causing graft versus host disease. The present invention identifies the main subpopulation (55-65%) of CD8 + /TCR −  facilitating cells (FQ as plasmacytoid precursor dendritic cells (p-preDC). The present invention notably demonstrates that FC and p-preDC share many phenotypic, morphological, functional features, including IFN-α production, activation and survival after stimulation, and expansion and maturation after FIO-Ligand (FL) treatment. FL mobilized FC, the majority of which express a pre-DC phenotype, facilitate HSC engraftment. Although p-preDC significantly enhance HSC engraftment, they do so with less efficiency than FC. The present invention for the first time defines a direct functional role for p-preDC in HSC engraftment and will have a significant impact on strategies to design effective facilitating cell-based therapies for transplantation.
The invention relates to a Chinese traditional medicine, that is, a medicine used for treating prostatitis. The invention is prepared by the following raw materials by weight: 3-8g of vermilion, 5-15g of realgar, 3-8g of mercury sulphide, 10-25g of red lead, 1.5-4g of borneol, 0.2-0.8g of muskiness and 10-25g of calcined alum. Capsule is preferential. The invention has the efficacies of clearing away heat and toxic material, removing stasis, resolving masses, removing obstruction of orifices and promoting urination. The invention is suitable for treating the diseases of cystitis, nephritis, odynuria, hematuria, urgency of micturition, prostatomegaly, prostatic hyperplasia and prostatitis. Through clinical oral administration of 60 cases, in a period of 6-8 days, the cure rate is 53 percent, the obvious effective rate is 88 percent and the effective rate is 100 percent.
There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.
Subjects in the LP group train on a custom built, computer controlled, linear electric motor powered leg press device. The so called "swinging" vibrational-proprioceptive mode is used, which means that constant velocity of the pedals (0.3 m/s and 0.2 m/s for concentric and eccentric phase, respectively) are interrupted by short stops (every 8 mm), resulting in short force peaks appearing throughout the movement. Training load is progressively increased throughout the training.